The drugs identified for negotiation in the second round include: Ozempic, Wegovy and other GPL-inhibitors are in high demand in the U.S. Due to that demand, Medicare covering them for diabetes ...

Supplies of high-demand obesity treatments are improving, but that doesn’t mean they're easier to get. Many employers and ...

Supplies of high-demand obesity drugs are improving – but they’re not easier to get - ‘There are a lot of people right now ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Ozempic/Wegovy is the first drug on HHS's 2025 list of Medicare price negotiations. As the leaders of the pharmaceutical industry boarded their planes to come home from the JP Morgan Healthcare ...

The next round of Medicare's historic drug price negotiations could save billions for seniors taking medications like Ozempic ...

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...

While Ozempic is covered by most health plans, weight loss drugs such as Wegovy are not currently covered by Medicare and other insurance. Don't expect a 20% S&P 500 three-peat this year ...

The approval for Wegovy opened the door for Part D coverage, as Medicare is forbidden from covering weight-loss drugs otherwise. This year marks the first plan year that Wegovy will be covered by ...